[EN] NOVEL MODULATORS OF CORTICAL DOPAMINERGIC- AND NMDA-RECEPTOR-MEDIATED GLUTAMATERGIC NEUROTRANSMISSION [FR] NOUVEAUX MODULATEURS DE NEUROTRANSMISSION GLUTAMATERGIQUE CORTICALE À MÉDIATION DOPAMINERGIQUE ET PAR RÉCEPTEUR NMDA
[EN] NOVEL MODULATORS OF CORTICAL DOPAMINERGIC- AND NMDA-RECEPTOR-MEDIATED GLUTAMATERGIC NEUROTRANSMISSION [FR] NOUVEAUX MODULATEURS DE NEUROTRANSMISSION GLUTAMATERGIQUE CORTICALE À MÉDIATION DOPAMINERGIQUE ET PAR RÉCEPTEUR NMDA
NOVEL MODULATORS OF CORTICAL DOPAMINERGIC- AND NMDA-RECEPTOR-MEDIATED GLUTAMATERGIC NEUROTRANSMISSION
申请人:SONESSON Clas
公开号:US20150148426A1
公开(公告)日:2015-05-28
The present invention relates to novel substituted phenoxyethylamine derivatives, useful as modulators of cortical and basal ganglia dopaminergic and N-methyl-D-aspartate (NMDA) receptor-mediated glutamatergic neurotransmission. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.
Modulators of cortical dopaminergic- and NMDA-receptor-mediated glutamatergic neurotransmission
申请人:Sonesson Clas
公开号:US09006227B2
公开(公告)日:2015-04-14
The present invention relates to novel substituted phenoxyethylamine derivatives, useful as modulators of cortical and basal ganglia dopaminergic and N-methyl-D-aspartate (NMDA) receptor-mediated glutamatergic neurotransmission. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.
[EN] NOVEL MODULATORS OF CORTICAL DOPAMINERGIC- AND NMDA-RECEPTOR-MEDIATED GLUTAMATERGIC NEUROTRANSMISSION<br/>[FR] NOUVEAUX MODULATEURS DE NEUROTRANSMISSION GLUTAMATERGIQUE CORTICALE À MÉDIATION DOPAMINERGIQUE ET PAR RÉCEPTEUR NMDA
申请人:NEUROSEARCH AS
公开号:WO2012143337A1
公开(公告)日:2012-10-26
The present invention relates to novel substituted phenoxyethylamine derivatives, useful as modulators of cortical and basal ganglia dopaminergic and N-methyl-D-aspartate (NMDA) receptor-mediated glutamatergic neurotransmission. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.